Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292872 · ClinicalTrials.gov registry record
Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
A clinical trial, sponsored by Intercept Pharmaceuticals.
- Completed
- Registry status
- 4,577
- Enrollment target
NCT05292872 is a clinical trial that has completed, run by Intercept Pharmaceuticals. The registered enrollment target is 4,577 participants.
The verdict
NCT05292872 has completed, sponsored by Intercept Pharmaceuticals.
- COMPLETED
- Registry status
- 4,577 participants
- Enrollment target
Study Summary
This is an observational, retrospective cohort study of patients with primary biliary cholangitis (PBC) who failed ursodeoxycholic acid (UDCA) treatment, using a real-world data source, the Komodo Health United States (US) claims database. The study is designed to evaluate the effectiveness of obeticholic acid (OCA). All patients who meet diagnostic criteria for PBC in the database between 01 Jun 2015 and 31 Dec 2021 and who meet all eligibility criteria were considered for this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,577 participants |
| Start Date | 2015-06-01 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292872
The ClinicalTrials.gov registry entry for NCT05292872 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,577 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05292872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292872 about?
NCT05292872 is a clinical study titled "Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients". This is an observational, retrospective cohort study of patients with primary biliary cholangitis (PBC) who failed ursodeoxycholic acid (UDCA) treatment, using a real-world data source, the Komodo Health United States (US) claims database. The study is designed to evaluate the effectiveness of obeti...
What is the current status of trial NCT05292872?
This trial is currently completed. The enrollment target is 4,577 participants. The study started on 2015-06-01. Estimated completion is 2021-12-31.
Who is sponsoring clinical trial NCT05292872?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.